MURRIETA, CA--(Marketwire - January 09, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today released its January 2008 investor newsletter, which highlights the recent announcement of planned clinical trials for Zonda's rapid, point of care Chlamydia product.
